Vaccine protection against Staphylococcus aureus pneumonia by Wardenburg, Juliane Bubeck & Schneewind, Olaf
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
JEM © The Rockefeller University Press  $30.00
Vol. 205, No. 2,  February 18, 2008  287-294  www.jem.org/cgi/doi/
287
10.1084/jem.20072208
BRIEF DEFINITIVE REPORT
             Staphylococcus aureus   is an important human 
pathogen that, in addition to soft tissue and 
bloodborne infections, causes pneumonia in 
adult and pediatric populations (  1  ). Several re-
ports have described the growing incidence 
of severe   S. aureus   pneumonia in otherwise 
healthy individuals, often caused by methicil-
lin-resistant   S. aureus   (MRSA) (  2, 3  ). Further, 
  S. aureus   is one of the most common causes of 
ventilator-assisted pneumonia associated with 
signifi  cant morbidity and mortality (  4  ). We re-
cently developed an animal model of   S. aureus    –
  induced pneumonia in adult, immunocompetent 
C57BL/6J mice that closely mimics the clini-
copathological features of human disease (  5  ). 
Using this experimental system and the human 
clinical   S. aureus   isolate Newman (  6  ), the con-
tributions of surface proteins and exotoxins to-
ward the pathogenesis of pneumonia were 
documented (  5  ) by revealing virulence defects 
in sortase A and accessory gene regulator A 
mutant strains that are either unable to display 
cell wall  –  anchored surface proteins (  7  ) or can-
not express factors destined for secretion into 
the extracellular medium (  8  ), respectively. 
    S. aureus       -hemolysin (Hla; also known as 
    -toxin) is the founding member of a family of 
bacterial pore-forming     -barrel toxins (  9, 10  ). 
Its structural gene,   hla  , is located on the chro-
mosome of   S. aureus   strains, most of which se-
crete the 293-residue water-soluble monomer 
(  11  ). Hla is known to play a role in the patho-
genesis of staphylococcal disease, as   S. aureus   
mutants lacking   hla   display reduced virulence in 
invasive disease models. In these experimental 
systems, larger numbers of staphylococci are 
required to kill mice after either i.p. or intra-
mammary infection (  12, 13  ). Further supporting 
the role of Hla in virulence, passive immuniza-
tion of mice with anti-Hla antisera aff  ords pro-
tection from challenge both with purifi  ed toxin 
as well as live staphylococci in the i.p. infection 
model (  14  ). 
  Hla is thought to engage surface receptors of 
sensitive host cells, thereby promoting toxin 
oligomerization into a heptameric prepore and 
insertion of a     -barrel structure with a 2-nm 
pore diameter into the plasma membrane (  15  ). 
Hla pores form in lymphocytes, macrophages, 
alveolar epithelial cells, pulmonary endothelium, 
and erythrocytes; however, granulocytes and fi  -
broblasts appear resistant to lysis (  9, 16  ). Instilla-
tion of purifi  ed Hla into rabbit or rat lung tissue 
triggers vascular leakage and pulmonary hyper-
tension, which has been at  tributed to the release 
of diff  erent signaling molecules (e.g., phosphati-
dyl inositol, nitric oxide, prostanoids, and throm-
boxane A  2  ) (  16  –  19  ). In agreement with the 
biochemical properties of Hla, mutations that ab-
rogate   hla   expression in   S. aureus   Newman abol-
ish virulence in the mouse pneumonia model (  5  ). 
We therefore examined Hla as a target for the 
development of vaccines that combat   S. aureus   
lung infection. 
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observed in Hla  H35L  -immunized animals (P = 0.001; 10 ani-
mals per group;   Fig. 2 A  ).   This decrease correlated with a re-
duction in   S. aureus   CFU recovered from the lung at 24 h after 
infection (P = 0.012; 10 animals per group;   Fig. 2 B  ). Gross 
pathological analysis of infected lung tissues revealed focal areas 
of consolidation in Hla  H35L  -immunized animals, in contrast to 
the diff  use consolidation observed in PBS-immunized animals 
(  Fig. 2 C  ); these observations were mirrored in histopathologic 
sections of infected lung tissue. The majority of alveolar space 
in mock-immunized animals was obliterated by infl  ammatory 
exudate, immune cell infi  ltrate, and staphylococci (  Fig. 2 D  ). 
In contrast, lesions in Hla  H35L  -immunized animals were dis-
crete and surrounded by large unaff  ected areas of lung tissue 
(  Fig. 2 E  ). To examine the eff  ect of immunization on the patho-
genesis of lung infections caused by clinically relevant   S. aureus   
isolates, Hla  H35L  -immunized animals were infected via the i.n. 
route with LAC or MW2 (10 animals per group). Although the 
    RESULTS AND DISCUSSION   
  Hla and the mortality of staphylococcal lung infections 
  Informed by the absolute genetic requirement of   hla   in   S. aureus   
strains Newman and LAC for the pathogenesis of pneumonia 
(  5, 20  ), we asked whether strain-based diff  erences in the level 
of Hla secretion correlate with disease severity. As a test for 
this conjecture, groups of 10 animals each were infected via the 
intranasal (i.n.) route with the community-associated MRSA 
(CA-MRSA) isolates LAC (USA 300, capsular polysaccharide 
[CP] type 5) (  21, 22  ) and MW2 (USA400, CP type 8) (  3  ), the 
methicillin-sensitive   S. aureus   (MSSA) isolate Newman (CP 
type 5), and the isogenic variants of LAC and Newman with 
a   bursa aurealis   insertion in   hla   (  hla::erm  ). The Newman   hla::erm   
mutant was transformed with plasmid vector (vector) or a 
complementing plasmid encoding Hla (p  hla  ). Animals were 
infected with 3  –  4   ×   10  8   CFU of each isolate, and mortality 
from pneumonia was recorded after infection (  Fig. 1  ) (  5  ).   
Animals infected with LAC or the Newman   hla::erm   variant 
harboring p  hla   were highly susceptible to pneumonia and died 
rapidly compared with animals infected with wild-type strain 
Newman (P = 0.017 and 0.00001, respectively, at 12 h; and 
P = 0.03 for both at 24 h;   Fig. 1 A  ). In contrast, animals infected 
with MW2 displayed even fewer symptoms and signs of dis-
ease and less mortality (P = 0.046 at 24 h;   Fig. 1 A  ). As expected, 
the Newman   hla::erm   variant carrying vector alone was com-
pletely avirulent (  5  ), as was the LAC   hla::erm   mutant (  Fig. 1 A  ). 
Immunoblotting of samples derived from various   S. aureus   
strains grown to equal cell density revealed the relative abun-
dance of Hla secretion in the extracellular medium (  Fig. 1 B  ); 
densitometry readings from each strain were obtained, normal-
ized to the signal derived from   S. aureus   Newman, and recorded 
as [Hla] (  Fig. 1 B  ). A comparison of the signal density of Hla in 
the immunoblot with animal mortality at 12, 24, and 48 h 
revealed correlation coeffi   cients of 0.96, 0.96, and 0.9, respec-
tively. Thus, not only is Hla required for the pathogenesis of 
  S. aureus   pneumonia, as we have previously demonstrated (  20  ), 
but the relative level of Hla expression by distinct   S. aureus   strains 
also correlates with the virulence properties of the organism. 
  Immunization with Hla  H35L   protects against   S. aureus   
pneumonia 
  The essential role of Hla in the pathogenesis of   S. aureus   pneu-
monia raised the possibility that antibody-mediated antagonism 
of toxin activity may protect experimental animals from disease. 
To test whether Hla-specifi  c immune responses aff  ect the 
pathogenesis of staphylococcal pneumonia, 4-wk-old mice 
were injected i.m. with a mock control (PBS) emulsifi  ed in 
CFA or were immunized with 20   μ  g of purifi  ed Hla  H35L   emul-
sifi  ed in CFA, then boosted 10 d later with the same amount 
of antigen (or PBS) in IFA. Hla  H35L  , a variant toxin with a sin-
gle amino acid substitution, cannot form cytolytic pores but 
retains the ability to bind its putative receptor on host target 
cells (  14, 23  ). At the time of challenge, a mean Hla  H35L  -specifi  c 
antibody titer of 1:5,601   ±   2,789 was measured in the serum 
of immunized animals. Upon i.n. challenge with 3  –  4   ×   10  8   
CFU   S. aureus   Newman, a signifi  cant decrease in mortality was 
    Figure 1.           S. aureus   secretion of Hla correlates with mortality from 
lung infection.   (A) Animals infected via the i.n. route (10 animals per 
group)  with  3 – 4   ×   10 8   wild-type   S. aureus   LAC, MW2, and Newman 
strains or the Hla-defi  cient strain (  hla::erm  ) complemented with either 
vector or p  hla   revealed strain-dependent differences in mortality. LAC and 
Newman   hla::erm   p hla   caused marked mortality at 12 h (P = 0.017 and 
0.00001, respectively) and 24 h (P = 0.03 for both strains) compared with 
Newman wild-type. In contrast, infection with the MW2 strain resulted in 
a lower mortality compared with Newman (P = 0.046); infection with LAC 
  hla::erm   and Newman   hla::erm   demonstrated these strains to be avirulent. 
Statistical signifi  cance is indicated by an asterisk. (B) Strain-based differ-
ences in the level of Hla secretion. Immunoblot analysis of 18-h culture 
supernatants revealed increased Hla production by LAC and Newman   hla::erm  
p  hla   compared with wild-type Newman, whereas MW2 produces lesser 
amounts of Hla. Amounts of Hla ([Hla]) secreted by each strain were 
quantifi  ed by evaluation of chemiluminescence signals derived from anti-
body binding to antigen and were recorded relative to the amount of Hla 
secreted by Newman.     JEM VOL. 205, February 18, 2008  289
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absolute mortality caused by these strains diff  ered from each 
other, as previously demonstrated (  20  ), signifi  cant protection 
was achieved in all Hla  H35L  -immunized animals (P = 0.00001 
for LAC; P = 0.018 for MW2;   Fig. 2 F  ). Importantly, this pro-
tection was observed over a 1-wk course after infection with 
the Newman, LAC, and MW2 isolates (  Fig. 2 G  ), indicat  -
ing that disease progression is blocked, not simply delayed, in 
presentation. Thus, active immunization targeting Hla protects 
animals from   S. aureus   pneumonia; this protection correlates with 
reduced microbiologic and pathological evidence of disease. 
  Anti-Hla prevents   S. aureus   injury of human lung cells 
  Several reports have described species-specifi  c eff  ects of   S. aureus   
virulence factors in the pathogenesis of disease; among these 
are the phage-encoded chemotaxis inhibitory protein of   S. aureus   
and staphylococcal complement inhibitor, immunomodula-
tory proteins that specifi  cally antagonize the function of the 
human immune system (  24  ). Similarly, rabbit erythrocytes are 
1,000-fold more sensitive to Hla-induced cytolysis than human 
erythrocytes (  9  ). To assess the contribution of Hla to the in-
jury of human lung tissue, we analyzed the eff  ects of   S. aureus   
clinical isolates on human A549 alveolar epithelial cells, which 
have been used to model human pulmonary epithelia in a diverse 
array of biological and physiological studies (  25, 26  ). When 
infected with   S. aureus   Newman, A549 injury was observed 
by microscopic evaluation of cells stained with a live/dead 
(green/red) reagent (  Fig. 3  ).   Uninfected cells reveal the stellate 
nature of the A549 line (  Fig. 3 A  ); co-culture of A549 cells 
with live Newman in the presence of PBS (  Fig. 3 B  ) or nor-
mal rabbit sera (NRS;   Fig. 3 C  ) revealed cell death. Addition 
of rabbit anti-Hla (    -Hla) to   S. aureus   Newman  –  infected cul-
tures led to marked reduction in A549 injury (  Fig. 3 D  ). 
Furthermore, the addition of purifi  ed Hla  H35L   (at a concentra-
tion of 10   μ  g/ml) also aff  orded protection against staphylococ-
cal cell injury (  Fig. 3 E  ), presumably through its ability to bind 
to the A549 cell membrane and antagonize the function of the 
wild-type toxin (not depicted) (  23  ).   S. aureus hla::erm   variants 
were unable to destroy A549 cells (  hla::erm   vector;   Fig. 3 F  ), a 
defect that was complemented by plasmid-encoded expression 
of Hla (  hla::erm   p  hla  ;   Fig. 3 G  ). Cellular injury in this co-culture 
system was quantitated by a lactate dehydrogenase (LDH) cyto-
toxicity assay (  Fig. 3 H  ) in which all conditions were scored 
as the percent maximal lysis obtained after detergent treatment 
of A549 cells. Upon demonstration of signifi  cance in the anal-
ysis of variance test (F = 284.72; P   <   0.001), the signifi  cance 
of these studies was assessed via Dunnett  ’  s post-test, in which 
the critical q value (0.05) was calculated to be 2.94. Treatment 
of infected A549 cells with either PBS or NRS resulted in cell 
lysis that was 23 and 26% maximal, respectively (Q  NRS   = 1.347). 
Treatment of   S. aureus   Newman  –  infected cells with either 
    -Hla rabbit antisera or purifi  ed Hla  H35L   abrogated the cyto-
toxic eff  ect (Q      -Hla   = 7.173; Q  HlaH35L   = 8.045). Co-culture 
with a   S. aureus hla::erm   variant transformed with vector failed to 
cause A459 injury (Q    hla::erm       vector   = 8.917), whereas plasmid-based 
expression of Hla resulted in massive cell death (Q    hla::erm       p      hla     = 
24.919). Collectively, these data demonstrate the critical role of 
Hla in human alveolar cell injury and suggest that antagonism of 
Hla markedly diminishes the ability of   S. aureus   to eff  ect injury 
to the pulmonary epithelium. 
  Passive transfer of anti-Hla protects against   S. aureus   
pneumonia 
  To test whether Hla-specifi  c antibodies can protect against 
  S. aureus   lung disease, animals were passively immunized with 
100   μ  l of either NRS or rabbit anti-Hla via i.p. injection 24 h 
before i.n. challenge with   S. aureus   Newman; the mean Hla  H35L  -
specifi  c serum antibody titer at the time of infection was 1:480   ±   
179 (  Fig. 4  ).   Examination of pneumonia-induced mortality 
revealed protection via transfer of anti-Hla serum but not with 
control serum (P = 0.018; 10 animals per group;   Fig. 4 A  ). 
Signifi  cant decreases in CFU recovered from the lungs of anti-
Hla  –  immunized animals were observed (P = 0.022; 10 animals 
per group;   Fig. 4 B  ); this protection correlated with improve-
ments in gross (  Fig. 4 C  ) and histopathologic (  Fig. 4, D and E  ) 
features of disease. Passive immunoprotection was also eff  ec-
tive in animals infected with the clinical isolates LAC and 
MW2 (P = 0.028 and 0.04, respectively; 10 animals per group; 
  Fig. 4 F  , left). Further demonstrating the specifi  city of this pas-
sive immunoprotection, the treatment of animals with rabbit 
antisera raised against Panton-Valentine leukocidin (PVL) (  20  ), 
a bicomponent pore-forming secreted cytotoxin of   S. aureus  , 
did not confer protection against   S. aureus   LAC pneumonia 
(P = 0.45; 10 animals per group;   Fig. 4 F  , right). This result is 
in agreement with previous work demonstrating that PVL is 
dispensable for the pathogenesis of lethal MRSA and MSSA 
lung infections in C57BL/6J mice (  20  ). 
  To defi  ne the nature of the host response to passive 
immunization, we evaluated serum cytokine responses in im-
munized animals 24 h after infection with   S. aureus   Newman. 
When compared with mock-immunized controls, animals 
receiving anti-Hla sera displayed blunted secretion of IL-1     
(P = 0.039; nine animals per group;   Fig. 4 G  ), an infl  amma-
tory cytokine that is the hallmark of acute lung injury (  27  ); 
anti-Hla  –  immunized animals also displayed increased release 
of IFN-     (P = 0.034), a cytokine that promotes phagocytic 
uptake and killing of   S. aureus   by immune cells (  28  ). Thus, 
immunization with anti-Hla antisera protects animals from 
  S. aureus   pneumonia, correlating with favorable alterations in 
the cytokine profi  le of the host. 
  For many years,   S. aureus   has been recognized as a promi-
nent cause of pneumonia in intensive care units (  29  ). The recent 
spread of highly virulent CA-MRSA strains in communities 
has caused dramatic changes in epidemiology and disease inci-
dence, demanding the development of novel preventive and 
therapeutic strategies (  29  ).   S. aureus   Hla is a well-characterized 
toxin (  10  ). When administered in purifi  ed form to lung tissues 
or to alveolar epithelial cells, Hla disrupts the integrity of cel-
lular membranes and perturbs lung function by precipitating 
the accumulation of infl  ammatory exudate within alveoli (  19  ). 
We recently expanded the analysis of Hla and examined the 
genetic requirements of its structural gene (  hla  ) toward the 
pathogenesis of pneumonia in experimental animals using 290 VACCINE AGAINST STAPHYLOCOCCAL PNEUMONIA | Wardenburg and Schneewind
    Figure 2.         Immunization with Hla  H35L   protects mice against   S. aureus   pneumonia.   (A) C57BL/6J mice were immunized by i.m. injection with PBS or 
20   μ g  Hla H35L  , a mutant Hla with a single amino acid substitution that abolishes toxin activity, and challenged with   S. aureus   Newman. Mortality was 
recorded 24, 48, or 72 h after infection (P = 0.001; 10 animals per group). (B) Immunization of mice with Hla  H35L   reduces the growth of   S. aureus   Newman 
in infected lung tissue (P = 0.012; 10 animals per group). Horizontal bars indicate the mean of bacterial load measurements. (C) Gross pathology of 
  S. aureus   Newman  –  infected lung tissue from mice that were immunized with PBS or Hla  H35L  . (D and E) Histopathology of   S. aureus   Newman – infected JEM VOL. 205, February 18, 2008  291
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To the best of our knowledge, this work represents the fi  rst 
successful implementation of this strategy for lung disease, 
revealing that active immunization of animals with a nontoxic 
Hla variant as well as passive immunoprotection via trans-
fer of Hla-specifi  c antisera can disrupt the pathogenesis of 
  S. aureus   pneumonia. 
pairwise comparisons of fully virulent   S. aureus   isolates and 
their isogenic   hla   variants (  5, 20  ). An absolute requirement for 
  hla   in disease pathogenesis was observed in   S. aureus   MSSA 
and MRSA strains (  5, 20  ). Thus, targeting the toxin activity of 
Hla via immunization would represent an exciting opportu-
nity to improve the poor prognosis of   S. aureus   pneumonia. 
lung tissue from mice that were immunized with PBS or Hla  H35L  . The arrow in E points to the focal area of consolidation in lung tissue of Hla  H35L -
immunized animals. Bars: (top) 0.1 cm; (bottom) 10     m. (F) Hla  H35L  -immunized C57BL/6J mice were challenged via the i.n. route with   S. aureus   CA-MRSA 
strains LAC or MW2 (10 animals per group). Mortality was recorded 24, 48, or 72 h after infection. The mortality of Hla  H35L  -immunized animals was 
signifi  cantly reduced over that of mock (PBS)-immunized animals challenged with either   S. aureus   LAC (P = 0.00001) or MW2 (P = 0.018). Statistical 
signifi  cance in A and F is indicated by an asterisk. (G) Survival curves of either unvaccinated or Hla  H35L  -immunized animals over a 168-h time course after 
infection with   S. aureus   Newman (left), LAC (middle), or MW2 (right).     
 
    Figure 3.           S. aureus   injury of human alveolar epithelial cells is reduced by antagonism of Hla.   Live (green)/dead (red) imaging of human A549 
cells was captured by fl  uorescence microscopy 4 h after infection. A549 cells were left uninfected (A) or co-cultured with   S. aureus   Newman in media 
treated with PBS (1:1,000; B), NRS (1:1,000; C), anti-Hla rabbit sera (    -Hla; 1:1,000; D), or purifi  ed Hla  H35L   (10     g/ml; E). Infections were also performed 
with the Newman isogenic   hla   insertion mutant,   hla::erm  , transformed with vector (F) or p  hla   (G). Bars, 20     m. (H) Assessment of LDH release by A549 
cells that were lysed during   S. aureus   infection. A signifi  cant reduction in LDH release was observed compared with PBS-treated cultures upon addition of 
anti-Hla sera or Hla  H35L  , whereas an increase in LDH release was observed upon co-culture with   S. aureus hla::erm   p hla .     Error  bars  indicate  mean   ±   SD.292 VACCINE AGAINST STAPHYLOCOCCAL PNEUMONIA | Wardenburg and Schneewind
    Figure 4.         Passive immunization of mice with anti-Hla protects against   S. aureus   lung infection.   (A) Mice were passively immunized by i.p. injection 
with NRS or rabbit serum that harbored anti-Hla and were challenged via the i.n. route with   S. aureus   Newman (P = 0.018; 10 animals per group). 
Mortality was recorded 24, 48, and 72 h after infection. Passive i.p. immunization of mice with anti-Hla reduces the ability of   S. aureus   Newman to grow 
in mouse lung tissue (P = 0.022; 10 animals per group; B) and decreases the gross pathological (C) and histopathologic (D and E) lesions evident after 
infection. Horizontal bars in B indicate the mean. Bars: (D and E, top) 0.1 cm; (D and E, bottom) 10     m. (F) i.p. administration of anti-Hla antisera protects 
animals upon challenge by i.n. inoculation with LAC (P = 0.028) or MW2 (P = 0.04; 10 animals per group; left), whereas immunization with anti-PVL 
immune sera does not confer protection (P = 0.45; 10 animals per group; right). Statistical signifi  cance in A and F is indicated by an asterisk. (G) Cytokine 
responses during lung infection are infl  uenced by passive immunization with antibodies against Hla. Serum cytokine levels were determined 24 h after 
infection, revealing a decrease in IL-1     secretion in anti-Hla  –  immunized animals (P = 0.039) and a corresponding increase in serum IFN-     (P = 0.034) 
relative to sham-immunized animals (nine animals per group). Horizonal bars indicate the mean.     JEM VOL. 205, February 18, 2008  293
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protein in IFA on day 10. Animals were challenged with   S. aureus   on day 21. 
Sera were collected before immunization and on day 20 to assess specifi  c anti-
body production. For passive immunization studies, 7-wk-old mice received 
100   μ  l of either NRS or toxin-specifi  c rabbit antisera via i.p. injection 24 h 
before challenge. 
  To assess the pathological correlates of pneumonia, infected animals were 
killed via forced CO  2   inhalation before removal of both lungs. The right lung 
was homogenized for enumeration of lung bacterial load. The left lung was 
placed in 1% formalin and paraffi   n embedded, thin sectioned, stained with 
hematoxylin-eosin, and analyzed by microscopy. 
  ELISA.     Serum antibody titers were determined with immunoplates (MaxiSorp; 
Thermo Fisher Scientifi  c) coated with 1   μ  g/ml Hla  H35L  . Serum dilutions were 
incubated in the appropriate plates, developed with horseradish peroxidase  –
  conjugated secondary antibodies and Opti-EIA (BD Biosciences), and read 
on a spectrophotometer (GENios; Tecan). 
  Protein and cytokine analysis.       S. aureus   cultures adjusted for OD were 
precipitated with trichloroacetic acid, washed in acetone, and protein solu-
bilized in sample buff  er before SDS-PAGE and anti-Hla (Toxin Technol-
ogy, Inc.) immunoblot. Sera harvested 24 h after infection were assayed for 
cytokine content (Bioplex Mouse 8-Plex A; Bio-Rad Laboratories). 
  Live/dead and cytotoxcity assays.     A549 cells were washed and plated in 
F12K media at a density of 1.5   ×   10  4   cells per well. For both assays, washed 
A549 cells were cultured with 100   μ  l of staphylococcal suspension per well in 
F12K media. After 4 h of incubation at 37  °  C, cells were treated with either 
live/dead (green/red) reagent (Invitrogen), or LDH activity was determined 
(Roche) according to the manufacturer  ’  s recommendations. Microscopic im-
ages of stained cells were obtained using a microscope (Eclipse TE2000U; 
Nikon); LDH activity was measured on a spectrophotometer. 
  Statistical analysis.     The statistical signifi  cance of mortality studies was de-
termined using Fisher  ’  s exact test. The signifi  cance of bacterial recovery 
from lungs was calculated using the two-tailed Student  ’  s   t   test. The signifi  cance 
of LDH release was calculated using analysis of variance and Dunnett  ’  s post-test. 
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  MRSA infection triggers a complex cascade of host responses 
in the lung, resulting in microvascular injury and accumulation 
of fl  uid and immune cells that impair respiratory function (  30  ). 
Pulmonary infl  ammation induced by both infectious and non-
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